

Melinda E Sanders

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1065797/publications.pdf>

Version: 2024-02-01

81
papers

15,373
citations

70961

41
h-index

82410

72
g-index

85
all docs

85
docs citations

85
times ranked

22103
citing authors

#	ARTICLE	IF	CITATIONS
1	Metabolic diversity within breast cancer brain-tropic cells determines metastatic fitness. <i>Cell Metabolism</i> , 2022, 34, 90-105.e7.	7.2	33
2	Atypical Ductal Hyperplasia-Ductal Carcinoma In Situ Spectrum: Diagnostic Considerations and Treatment Impact in the Era of Deescalation. <i>Surgical Pathology Clinics</i> , 2022, 15, 95-103.	0.7	4
3	Abstract PD3-04: Multi-omics characterization of triple-negative breast cancer identifies therapeutic vulnerabilities and epigenetic immune suppression in the mesenchymal subtype. <i>Cancer Research</i> , 2022, 82, PD3-04-PD3-04.	0.4	0
4	Abstract P1-04-03: Host myeloid response to tumor and immunotherapy is associated with heterogeneity in outcomes to anti-PDL1. <i>Cancer Research</i> , 2022, 82, P1-04-03-P1-04-03.	0.4	0
5	Peripheral Blood Monocyte Abundance Predicts Outcomes in Patients with Breast Cancer. <i>Cancer Research Communications</i> , 2022, 2, 286-292.	0.7	2
6	Abstract PS17-14: Evaluating the efficacy of immunotherapy in triple negative breast cancer. , 2021, , .		0
7	Hierarchical tumor heterogeneity mediated by cell contact between distinct genetic subclones. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	11
8	Tumor-Specific Major Histocompatibility-II Expression Predicts Benefit to Anti-PD-1/L1 Therapy in Patients With HER2-Negative Primary Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 5299-5306.	3.2	39
9	Multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypes. <i>Nature Communications</i> , 2021, 12, 6276.	5.8	89
10	245...Host myeloid response to tumor and immunotherapy is associated with heterogeneity in outcomes to anti-PDL1. , 2021, 9, A264-A264.		0
11	318...Enforced tumor specific MHC-I heterogeneity in triple negative breast cancer drives immunotherapy resistance. , 2021, 9, A342-A342.		1
12	Noninvasive Follicular Thyroid Neoplasm With Papillary-Like Nuclear Features in Children: An Institutional Experience and Literature Review. <i>Pediatric and Developmental Pathology</i> , 2020, 23, 121-126.	0.5	11
13	TBCRC 032 IB/II Multicenter Study: Molecular Insights to AR Antagonist and PI3K Inhibitor Efficacy in Patients with AR+ Metastatic Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 2111-2123.	3.2	91
14	Immunohistochemical analysis of IDH2 R172 hotspot mutations in breast papillary neoplasms: applications in the diagnosis of tall cell carcinoma with reverse polarity. <i>Modern Pathology</i> , 2020, 33, 1056-1064.	2.9	35
15	Proline rich 11 (PRR11) overexpression amplifies PI3K signaling and promotes antiestrogen resistance in breast cancer. <i>Nature Communications</i> , 2020, 11, 5488.	5.8	25
16	Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 5668-5681.	3.2	37
17	Targeting MYCN-expressing triple-negative breast cancer with BET and MEK inhibitors. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	46
18	The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immunology biomarkers in breast cancer clinical trials and daily practice. <i>Journal of Pathology</i> , 2020, 250, 667-684.	2.1	142

#	ARTICLE	IF	CITATIONS
19	MEK activation modulates glycolysis and supports suppressive myeloid cells in TNBC. JCI Insight, 2020, 5, .	2.3	22
20	A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis. Nature Medicine, 2019, 25, 1243-1250.	15.2	133
21	PIK3CA and MAP3K1 alterations imply luminal A status and are associated with clinical benefit from pan-PI3K inhibitor buparlisib and letrozole in ER+ metastatic breast cancer. Npj Breast Cancer, 2019, 5, 31.	2.3	31
22	Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data. Genome Medicine, 2019, 11, 34.	3.6	732
23	p73 regulates epidermal wound healing and induced keratinocyte programming. PLoS ONE, 2019, 14, e0218458.	1.1	20
24	Identification of Targetable Recurrent MAP3K8 Rearrangements in Melanomas Lacking Known Driver Mutations. Molecular Cancer Research, 2019, 17, 1842-1853.	1.5	11
25	Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer. Nature Communications, 2019, 10, 1373.	5.8	252
26	Enhancing Parathyroid Gland Visualization Using a Near Infrared Fluorescence-Based Overlay Imaging System. Journal of the American College of Surgeons, 2019, 228, 730-743.	0.2	30
27	Innovative surgical guidance for label-free real-time parathyroid identification. Surgery, 2019, 165, 114-123.	1.0	43
28	Extended Adjuvant Therapy with Neratinib Plus Fulvestrant Blocks ER/HER2 Crosstalk and Maintains Complete Responses of ER+/HER2+ Breast Cancers: Implications to the ExteNET Trial. Clinical Cancer Research, 2019, 25, 771-783.	3.2	29
29	DNA methyltransferase inhibition upregulates MHC-I to potentiate cytotoxic T lymphocyte responses in breast cancer. Nature Communications, 2018, 9, 248.	5.8	181
30	Risk Factors for Breast Carcinoma in Women With Proliferative Breast Disease. , 2018, , 264-271.e2.		1
31	Melanoma response to anti-PD-L1 immunotherapy requires JAK1 signaling, but not JAK2. Oncolmmunology, 2018, 7, e1438106.	2.1	54
32	Postâ€r radiation morphea of the breast: a case report and review of the literature. Histopathology, 2018, 72, 342-350.	1.6	18
33	Developing a Clinical Prototype to Guide Surgeons for Intraoperative Label-Free Identification of Parathyroid Glands in Real Time. Thyroid, 2018, 28, 1517-1531.	2.4	54
34	Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagement. JCI Insight, 2018, 3, .	2.3	128
35	MHC-II expression to drive a unique pattern of adaptive resistance to antitumor immunity through receptor checkpoint engagement.. Journal of Clinical Oncology, 2018, 36, 180-180.	0.8	10
36	Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired Resistance to CDK4/6 Inhibition in ER-Positive Breast Cancer. Cancer Research, 2017, 77, 2488-2499.	0.4	178

#	ARTICLE	IF	CITATIONS
37	Extracellular Matrix/Integrin Signaling Promotes Resistance to Combined Inhibition of HER2 and PI3K in HER2+ Breast Cancer. <i>Cancer Research</i> , 2017, 77, 3280-3292.	0.4	76
38	The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	89
39	PI3K Inhibition Reduces Mammary Tumor Growth and Facilitates Antitumor Immunity and Anti-PD1 Responses. <i>Clinical Cancer Research</i> , 2017, 23, 3371-3384.	3.2	80
40	MYC and MCL1 Cooperatively Promote Chemotherapy-Resistant Breast Cancer Stem Cells via Regulation of Mitochondrial Oxidative Phosphorylation. <i>Cell Metabolism</i> , 2017, 26, 633-647.e7.	7.2	449
41	An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	29
42	Association of FGFR1 with ER± Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER+ Breast Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 6138-6150.	3.2	94
43	Genomic profiling of ER ⁺ breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	91
44	Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors. <i>Advances in Anatomic Pathology</i> , 2017, 24, 111-135.	2.4	530
45	Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research. <i>Advances in Anatomic Pathology</i> , 2017, 24, 235-251.	2.4	469
46	The molecular basis of breast cancer pathological phenotypes. <i>Journal of Pathology</i> , 2017, 241, 375-391.	2.1	86
47	Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection. <i>PLoS ONE</i> , 2016, 11, e0157368.	1.1	975
48	Liposarcomatous differentiation in malignant phyllodes tumours is unassociated with <i>MDM2</i> or <i>CDK4</i> amplification. <i>Histopathology</i> , 2016, 68, 1040-1045.	1.6	31
49	Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 674-690.	12.5	1,938
50	Extent of atypical hyperplasia stratifies breast cancer risk in 2 independent cohorts of women. <i>Cancer</i> , 2016, 122, 2971-2978.	2.0	48
51	Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy. <i>Nature Communications</i> , 2016, 7, 10582.	5.8	412
52	Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence. <i>Science Translational Medicine</i> , 2016, 8, 334ra53.	5.8	105
53	Establishing the clinical utility of autofluorescence spectroscopy for parathyroid detection. <i>Surgery</i> , 2016, 159, 193-203.	1.0	160
54	RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors. <i>Clinical Cancer Research</i> , 2016, 22, 1499-1509.	3.2	428

#	ARTICLE	IF	CITATIONS
55	A Phyllodes-like Mammary Tumor in a Breeding Galago (<i>Otolemur garnettii</i>). <i>Comparative Medicine</i> , 2016, 66, 424-428.	0.4	0
56	Detection of microcalcifications by characteristic magnetic susceptibility effects using MR phase image cross-correlation analysis. <i>Medical Physics</i> , 2015, 42, 1436-1452.	1.6	8
57	Continued observation of the natural history of low-grade ductal carcinoma in situ reaffirms proclivity for local recurrence even after more than 30 years of follow-up. <i>Modern Pathology</i> , 2015, 28, 662-669.	2.9	106
58	Detection of breast cancer microcalcification using ^{99m} Tc-MDP SPECT or Osteosense 750EX FMT imaging. <i>Nuclear Medicine and Biology</i> , 2015, 42, 269-273.	0.3	9
59	Current HER2 Testing Recommendations and Clinical Relevance as a Predictor of Response to Targeted Therapy. <i>Clinical Breast Cancer</i> , 2015, 15, 171-180.	1.1	35
60	Kinome-wide Functional Screen Identifies Role of PLK1 in Hormone-Independent, ER-Positive Breast Cancer. <i>Cancer Research</i> , 2015, 75, 405-414.	0.4	53
61	Melanoma-specific MHC-II expression to predict response to ±PD-1 therapy. <i>Journal of Clinical Oncology</i> , 2015, 33, 9041-9041.	0.8	0
62	Interobserver Variability by Pathologists in the Distinction Between Cellular Fibroadenomas and Phyllodes Tumors. <i>International Journal of Surgical Pathology</i> , 2014, 22, 695-698.	0.4	77
63	Molecular Profiling of the Residual Disease of Triple-Negative Breast Cancers after Neoadjuvant Chemotherapy Identifies Actionable Therapeutic Targets. <i>Cancer Discovery</i> , 2014, 4, 232-245.	7.7	413
64	Analyzing Spatial Heterogeneity in DCE- and DW-MRI Parametric Maps to Optimize Prediction of Pathologic Response to Neoadjuvant Chemotherapy in Breast Cancer. <i>Translational Oncology</i> , 2014, 7, 14-22.	1.7	35
65	An Approach to Breast Cancer Diagnosis via PET Imaging of Microcalcifications Using ¹⁸ F-NaF. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1138-1143.	2.8	22
66	Quantitative Optical Imaging of Primary Tumor Organoid Metabolism Predicts Drug Response in Breast Cancer. <i>Cancer Research</i> , 2014, 74, 5184-5194.	0.4	251
67	PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors. <i>Breast Cancer Research</i> , 2014, 16, 406.	2.2	267
68	Stand Up to Cancer Phase Ib Study of Pan-Phosphoinositide-3-Kinase Inhibitor Buparlisib With Letrozole in Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 1202-1209.	0.8	159
69	SU2C phase Ib study of the PI3K± inhibitor BYL719 with letrozole in ER+/HER2± metastatic breast cancer (MBC). <i>Journal of Clinical Oncology</i> , 2014, 32, 516-516.	0.8	2
70	Discordant Cellular Response to Presurgical Letrozole in Bilateral Synchronous ER+ Breast Cancers with a KRAS Mutation or FGFR1 Gene Amplification. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 2301-2305.	1.9	22
71	Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance. <i>Nature Medicine</i> , 2012, 18, 1052-1059.	15.2	219
72	Clinicopathologic characteristics of carcinomas that develop after a biopsy containing columnar cell lesions. <i>Cancer</i> , 2012, 118, 2372-2377.	2.0	25

#	ARTICLE	IF	CITATIONS
73	Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. <i>Journal of Clinical Investigation</i> , 2011, 121, 2750-2767.	3.9	4,137
74	Can we know what to do when DCIS is diagnosed?. <i>Oncology</i> , 2011, 25, 852-6.	0.4	4
75	Differentiating Proteomic Biomarkers in Breast Cancer by Laser Capture Microdissection and MALDI MS. <i>Journal of Proteome Research</i> , 2008, 7, 1500-1507.	1.8	57
76	Adenoid Cystic Carcinoma of the Breast. , 2006, , 187-193.		2
77	Tubular Carcinoma. , 2006, , 230-235.		1
78	Interdependence of radial scar and proliferative disease with respect to invasive breast carcinoma risk in patients with benign breast biopsies. <i>Cancer</i> , 2006, 106, 1453-1461.	2.0	99
79	A Novel Histology-directed Strategy for MALDI-MS Tissue Profiling That Improves Throughput and Cellular Specificity in Human Breast Cancer. <i>Molecular and Cellular Proteomics</i> , 2006, 5, 1975-1983.	2.5	169
80	The natural history of low-grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long-term follow-up. <i>Cancer</i> , 2005, 103, 2481-2484.	2.0	419
81	Direct analysis of laser capture microdissected cells by MALDI mass spectrometry. <i>Journal of the American Society for Mass Spectrometry</i> , 2002, 13, 1292-1297.	1.2	153